vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and Ovintiv Inc. (OVV). Click either name above to swap in a different company.

Ovintiv Inc. is the larger business by last-quarter revenue ($2.1B vs $1.6B, roughly 1.2× Edwards Lifesciences). Ovintiv Inc. runs the higher net margin — 46.1% vs 23.1%, a 23.0% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs -6.0%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -7.2%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

Ovintiv Inc. is a U.S. petroleum company based in Denver. The company was formed in 2020 through a restructuring of its Canadian predecessor, Encana.

EW vs OVV — Head-to-Head

Bigger by revenue
OVV
OVV
1.2× larger
OVV
$2.1B
$1.6B
EW
Growing faster (revenue YoY)
EW
EW
+22.7% gap
EW
16.7%
-6.0%
OVV
Higher net margin
OVV
OVV
23.0% more per $
OVV
46.1%
23.1%
EW
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-7.2%
OVV

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EW
EW
OVV
OVV
Revenue
$1.6B
$2.1B
Net Profit
$380.7M
$946.0M
Gross Margin
78.0%
Operating Margin
1.8%
21.2%
Net Margin
23.1%
46.1%
Revenue YoY
16.7%
-6.0%
Net Profit YoY
6.8%
1676.7%
EPS (diluted)
$0.66
$3.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
OVV
OVV
Q1 26
$1.6B
Q4 25
$1.6B
$2.1B
Q3 25
$1.6B
$2.0B
Q2 25
$1.5B
$2.2B
Q1 25
$1.4B
$2.4B
Q4 24
$1.4B
$2.2B
Q3 24
$1.4B
$2.2B
Q2 24
$1.4B
$2.2B
Net Profit
EW
EW
OVV
OVV
Q1 26
$380.7M
Q4 25
$91.2M
$946.0M
Q3 25
$291.1M
$148.0M
Q2 25
$333.2M
$307.0M
Q1 25
$358.0M
$-159.0M
Q4 24
$385.6M
$-60.0M
Q3 24
$3.1B
$507.0M
Q2 24
$366.3M
$340.0M
Gross Margin
EW
EW
OVV
OVV
Q1 26
78.0%
Q4 25
78.1%
Q3 25
77.8%
Q2 25
77.5%
Q1 25
78.7%
Q4 24
78.9%
Q3 24
80.6%
Q2 24
79.9%
Operating Margin
EW
EW
OVV
OVV
Q1 26
1.8%
Q4 25
9.6%
21.2%
Q3 25
19.8%
13.5%
Q2 25
26.8%
23.1%
Q1 25
27.9%
-3.7%
Q4 24
22.6%
0.1%
Q3 24
25.9%
24.2%
Q2 24
26.8%
25.4%
Net Margin
EW
EW
OVV
OVV
Q1 26
23.1%
Q4 25
5.8%
46.1%
Q3 25
18.7%
7.3%
Q2 25
21.7%
13.9%
Q1 25
25.3%
-6.7%
Q4 24
27.8%
-2.7%
Q3 24
226.7%
23.3%
Q2 24
26.7%
15.5%
EPS (diluted)
EW
EW
OVV
OVV
Q1 26
$0.66
Q4 25
$0.16
$3.64
Q3 25
$0.50
$0.57
Q2 25
$0.56
$1.18
Q1 25
$0.61
$-0.61
Q4 24
$0.65
$-0.22
Q3 24
$5.13
$1.92
Q2 24
$0.61
$1.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
OVV
OVV
Cash + ST InvestmentsLiquidity on hand
$280.0M
Total DebtLower is stronger
$5.2B
Stockholders' EquityBook value
$11.2B
Total Assets
$20.4B
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
OVV
OVV
Q1 26
Q4 25
$4.2B
$280.0M
Q3 25
$3.8B
$25.0M
Q2 25
$4.1B
$20.0M
Q1 25
$3.9B
$8.0M
Q4 24
$4.0B
$42.0M
Q3 24
$4.4B
$9.0M
Q2 24
$2.0B
$8.0M
Total Debt
EW
EW
OVV
OVV
Q1 26
Q4 25
$5.2B
Q3 25
$5.2B
Q2 25
$5.3B
Q1 25
$5.5B
Q4 24
$5.5B
Q3 24
$5.9B
Q2 24
$6.1B
Stockholders' Equity
EW
EW
OVV
OVV
Q1 26
Q4 25
$10.3B
$11.2B
Q3 25
$10.2B
$10.2B
Q2 25
$10.5B
$10.4B
Q1 25
$10.1B
$10.1B
Q4 24
$10.0B
$10.3B
Q3 24
$9.5B
$10.7B
Q2 24
$7.4B
$10.3B
Total Assets
EW
EW
OVV
OVV
Q1 26
Q4 25
$13.7B
$20.4B
Q3 25
$13.3B
$19.4B
Q2 25
$13.5B
$19.7B
Q1 25
$13.0B
$19.6B
Q4 24
$13.1B
$19.3B
Q3 24
$13.0B
$19.9B
Q2 24
$10.1B
$19.8B
Debt / Equity
EW
EW
OVV
OVV
Q1 26
Q4 25
0.46×
Q3 25
0.51×
Q2 25
0.51×
Q1 25
0.55×
Q4 24
0.53×
Q3 24
0.55×
Q2 24
0.59×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
OVV
OVV
Operating Cash FlowLast quarter
$954.0M
Free Cash FlowOCF − Capex
$489.0M
FCF MarginFCF / Revenue
23.8%
Capex IntensityCapex / Revenue
22.6%
Cash ConversionOCF / Net Profit
1.01×
TTM Free Cash FlowTrailing 4 quarters
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
OVV
OVV
Q1 26
Q4 25
$450.9M
$954.0M
Q3 25
$573.7M
$812.0M
Q2 25
$290.2M
$1.0B
Q1 25
$280.4M
$873.0M
Q4 24
$-127.5M
$1.0B
Q3 24
$351.8M
$1.0B
Q2 24
$371.5M
$1.0B
Free Cash Flow
EW
EW
OVV
OVV
Q1 26
Q4 25
$353.5M
$489.0M
Q3 25
$516.2M
$268.0M
Q2 25
$240.9M
$492.0M
Q1 25
$224.4M
$256.0M
Q4 24
$-177.3M
$468.0M
Q3 24
$299.9M
$484.0M
Q2 24
$286.1M
$398.0M
FCF Margin
EW
EW
OVV
OVV
Q1 26
Q4 25
22.5%
23.8%
Q3 25
33.2%
13.3%
Q2 25
15.7%
22.2%
Q1 25
15.9%
10.8%
Q4 24
-12.8%
21.4%
Q3 24
22.1%
22.2%
Q2 24
20.9%
18.1%
Capex Intensity
EW
EW
OVV
OVV
Q1 26
Q4 25
6.2%
22.6%
Q3 25
3.7%
26.9%
Q2 25
3.2%
23.5%
Q1 25
4.0%
26.0%
Q4 24
3.6%
25.3%
Q3 24
3.8%
24.7%
Q2 24
6.2%
28.4%
Cash Conversion
EW
EW
OVV
OVV
Q1 26
Q4 25
4.94×
1.01×
Q3 25
1.97×
5.49×
Q2 25
0.87×
3.30×
Q1 25
0.78×
Q4 24
-0.33×
Q3 24
0.11×
2.02×
Q2 24
1.01×
3.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EW
EW

Segment breakdown not available.

OVV
OVV

Product And Service Revenue$1.7B84%
Sales Of Purchased Product$338.0M16%

Related Comparisons